Steroid-Sparing Therapy for Neurosarcoidosis

Relatively high rates of relapse occurred with either methotrexate or mycophenolate mofetil in a retrospective analysis.

Glucocorticoids are widely considered to be a first-line therapy for neurosarcoidosis, but steroid monotherapy is sometimes insufficient or the toxicity is prohibitive. Evidence to inform selection of steroid-sparing therapy for neurosarcoidosis is sparse, and practice patterns vary. Now, in an uncontrolled, retrospective study from four university hospitals in France, investigators compared relapse rates in neurosarcoidosis patients treated with two steroid-sparing regimens for at least 3 months.

Of 40 neurosarcoidosis patients, 32 were treated with methotrexate (MTX; at a median dose of 20 mg per week), and 14 were treated with mycophenolate mofetil (MMF; at a median dose of 2 grams per day); 6 patients had successive treatment with both a…

Reviewing Author

Jeffrey M. Gelfand, MD, MAS

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Jeffrey M. Gelfand, MD, MAS

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Steroid-Sparing Therapy for Neurosarcoidosis

Topics

Reviewing Author